Oppenheimer Downgrades Alnylam Pharmaceuticals to Perform
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has downgraded Alnylam Pharmaceuticals from Outperform to Perform.

October 11, 2023 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alnylam Pharmaceuticals has been downgraded from Outperform to Perform by Oppenheimer analyst Leland Gershell.
Analyst ratings often have a significant impact on a company's stock price. A downgrade from Outperform to Perform suggests that the analyst believes the company's stock will perform at the market average, rather than outperforming it. This could lead to a decrease in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100